Trial Profile
Randomized Phase II Study Of Immunization With Mage-3/Melan-A/gp100/NA17 Peptide-Pulsed Autologous PBMC And rhIL-12 With Or Without Low Dose IL-2 In Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-12 (Primary) ; Melanoma vaccine (Primary) ; Interleukin-2
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 May 2007 Status change
- 15 Oct 2005 New trial record.